Specificity | Clone | Host Species | Reactive Species | Format | Size | Reviews | Supplier | |
---|---|---|---|---|---|---|---|---|
SARS-CoV-2 | monoclonal | Mouse | n/a | antigen affinity purified | 50 µl, 100 µl, 200 µl, | n/a |
ABBEXA LTD |
More Info |
SARS-CoV-2 | polyclonal | Rabbit | n/a | antigen affinity purified | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
SARS-CoV-2 | polyclonal | Rabbit | n/a | antigen affinity purified | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Chimeric Human/Mouse | n/a | affinity purified | 50 µg, 100 µg, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Chimeric Human/Mouse | n/a | affinity purified | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Chimeric Human/Mouse | n/a | affinity purified | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Mouse | n/a | affinity purified | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Chimeric Human/Mouse | n/a | biotin conjugate | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Chimeric Human/Mouse | n/a | fluorescein (FITC) conjugate | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | polyclonal | Rabbit | n/a | immunogen affinity purified | 30 µl, 100 µl, 1 ml, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Chimeric Human/Mouse | n/a | peroxidase (HRP) conjugate | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Mouse | n/a | Protein A purified | 1 mg, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Mouse | n/a | Protein A purified | 1 mg, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Rabbit | n/a | unconjugated | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Chimeric Human/Mouse | n/a | unconjugated | 1 mg, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Chimeric Human/Mouse | n/a | unconjugated | 1 mg, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein | monoclonal | Recombinant Human | n/a | unconjugated | 100 µl, 1 ml, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein scFv | monoclonal | Recombinant | n/a | unconjugated | 100 µl, 1 ml, | n/a |
ABBEXA LTD |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D002 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2); | unconjugated | 100 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D002 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2); | unconjugated | 50 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV-2 RBD | DM54 | Rabbit | SARS-CoV-2 | unconjugated | 100 µg | n/a |
ORIGENE TECHNOLOGIES |
More Info |
SARS-CoV-2 RBD | DM55 | Rabbit | SARS-CoV-2 | unconjugated | 100 µg | n/a |
ORIGENE TECHNOLOGIES |
More Info |
SARS-CoV-2 Spike | DM42 | Rabbit | SARS-CoV-2 | unconjugated | 100 µg | n/a |
ORIGENE TECHNOLOGIES |
More Info |
SARS-CoV-2 Trimeric Spike 1 Protein | monoclonal | Mouse | n/a | Protein A purified | 1 mg, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) S1 Protein | monoclonal | Rabbit | n/a | unconjugated | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) S1 Protein | monoclonal | Recombinant Human | n/a | unconjugated | 100 µl, 1 ml, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Trimeric Spike 1 Protein | monoclonal | Mouse | n/a | Protein A purified | 1 mg, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Trimeric Spike 1 Protein | monoclonal | Mouse | n/a | Protein A purified | 1 mg, | n/a |
ABBEXA LTD |
More Info |
SARS-CoV-2 (COVID-19) Spike RBD domain | polyclonal | Sheep | n/a | unconjugated | 0.1 mg | n/a |
BIORBYT LTD. |
More Info |
Nucleocapsid (SARS-CoV-2) | polyclonal | Goat | SARS-CoV-2 | epitope affinity purified | 300 µg | n/a |
SICGEN ANTIBODIES |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D001 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Omicron (B.1.1.529); | unconjugated | 100 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D001 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Omicron (B.1.1.529); | unconjugated | 50 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D003 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2), SARS-CoV-2 Omicron (BA.1.1), SARS-CoV-2 Omicron (B.1.1.529), SARS-CoV-2 Omicron (BA.2), SARS-CoV-2 Omicron (BA.2.12.1), SARS-CoV-2 Omicron (BA.2.75.2), SARS-CoV-2 (BA.2.3.20), SARS-CoV-2 (BA.2.75), SARS-CoV-2 Omicron (BA.4), SARS-CoV-2 Omicron (BA.4.6 / BF.7), SARS-CoV-2 Omicron (BA.5), SARS-CoV-2 Omicron (BQ.1.1), SARS-CoV-2 Omicron (XBB) | unconjugated | 100 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D003 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2), SARS-CoV-2 Omicron (BA.1.1), SARS-CoV-2 Omicron (B.1.1.529), SARS-CoV-2 Omicron (BA.2), SARS-CoV-2 Omicron (BA.2.12.1), SARS-CoV-2 Omicron (BA.2.75.2), SARS-CoV-2 (BA.2.3.20), SARS-CoV-2 (BA.2.75), SARS-CoV-2 Omicron (BA.4), SARS-CoV-2 Omicron (BA.4.6 / BF.7), SARS-CoV-2 Omicron (BA.5), SARS-CoV-2 Omicron (BQ.1.1), SARS-CoV-2 Omicron (XBB) | unconjugated | 50 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D004 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2), SARS-CoV-2 Omicron (B.1.1.529), SARS-CoV-2 Omicron (BA.1.1), SARS-CoV-2 Omicron (BA.2), SARS-CoV-2 Omicron (BA.2.12.1), SARS-CoV-2 (BA.2.3.20), SARS-CoV-2 (BA.2.75), SARS-CoV-2 Omicron (BA.2.75.2), SARS-CoV-2 Omicron (BA.4), SARS-CoV-2 Omicron (BA.4.6 / BF.7), SARS-CoV-2 Omicron (BA.5), SARS-CoV-2 Omicron (BQ.1.1), SARS-CoV-2 Omicron (XBB) | unconjugated | 100 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D004 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2), SARS-CoV-2 Omicron (B.1.1.529), SARS-CoV-2 Omicron (BA.1.1), SARS-CoV-2 Omicron (BA.2), SARS-CoV-2 Omicron (BA.2.12.1), SARS-CoV-2 (BA.2.3.20), SARS-CoV-2 (BA.2.75), SARS-CoV-2 Omicron (BA.2.75.2), SARS-CoV-2 Omicron (BA.4), SARS-CoV-2 Omicron (BA.4.6 / BF.7), SARS-CoV-2 Omicron (BA.5), SARS-CoV-2 Omicron (BQ.1.1), SARS-CoV-2 Omicron (XBB) | unconjugated | 50 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D006 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2), SARS-CoV-2 Omicron (BA.1.1), SARS-CoV-2 Omicron (B.1.1.529), SARS-CoV-2 Omicron (BA.2), SARS-CoV-2 Omicron (BA.2.12.1), SARS-CoV-2 Omicron (BA.2.75.2), SARS-CoV-2 (BA.2.3.20), SARS-CoV-2 (BA.2.75), SARS-CoV-2 Omicron (BA.4), SARS-CoV-2 Omicron (BA.4.6 / BF.7), SARS-CoV-2 Omicron (BA.5), SARS-CoV-2 Omicron (BQ.1.1), SARS-CoV-2 Omicron (XBB) | unconjugated | 100 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D006 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2), SARS-CoV-2 Omicron (BA.1.1), SARS-CoV-2 Omicron (B.1.1.529), SARS-CoV-2 Omicron (BA.2), SARS-CoV-2 Omicron (BA.2.12.1), SARS-CoV-2 Omicron (BA.2.75.2), SARS-CoV-2 (BA.2.3.20), SARS-CoV-2 (BA.2.75), SARS-CoV-2 Omicron (BA.4), SARS-CoV-2 Omicron (BA.4.6 / BF.7), SARS-CoV-2 Omicron (BA.5), SARS-CoV-2 Omicron (BQ.1.1), SARS-CoV-2 Omicron (XBB) | unconjugated | 50 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV-2 (2019-nCoV) NSP13 | monoclonal | Rabbit | SARS-CoV-2 (2019-nCoV) | unconjugated | n/a | n/a |
CREATIVE BIOLABS, INC. |
More Info |
SARS-CoV-2 (2019-nCoV) NSP13 | monoclonal | Rabbit | SARS-CoV-2 (2019-nCoV) | unconjugated | n/a | n/a |
CREATIVE BIOLABS, INC. |
More Info |
SARS-CoV-2 (2019-nCoV) NSP13 | monoclonal | Rabbit | SARS-CoV-2 (2019-nCoV) | unconjugated | n/a | n/a |
CREATIVE BIOLABS, INC. |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D005 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2), SARS-CoV-2 Omicron (BA.1.1), SARS-CoV-2 Omicron (B.1.1.529), SARS-CoV-2 Omicron (BA.2), SARS-CoV-2 Omicron (BA.2.12.1), SARS-CoV-2 Omicron (BA.2.75.2), SARS-CoV-2 (BA.2.3.20), SARS-CoV-2 (BA.2.75), SARS-CoV-2 Omicron (BA.4), SARS-CoV-2 Omicron (BA.4.6 / BF.7), SARS-CoV-2 Omicron (BA.5), SARS-CoV-2 Omicron (BQ.1.1), SARS-CoV-2 Omicron (XBB) | unconjugated | 100 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD | D005 | Chimeric | SARS-CoV, SARS-CoV-2, SARS-CoV-2 Delta (B.1.617.2), SARS-CoV-2 Omicron (BA.1.1), SARS-CoV-2 Omicron (B.1.1.529), SARS-CoV-2 Omicron (BA.2), SARS-CoV-2 Omicron (BA.2.12.1), SARS-CoV-2 Omicron (BA.2.75.2), SARS-CoV-2 (BA.2.3.20), SARS-CoV-2 (BA.2.75), SARS-CoV-2 Omicron (BA.4), SARS-CoV-2 Omicron (BA.4.6 / BF.7), SARS-CoV-2 Omicron (BA.5), SARS-CoV-2 Omicron (BQ.1.1), SARS-CoV-2 Omicron (XBB) | unconjugated | 50 µL | n/a |
CAYMAN CHEMICAL COMPANY |
More Info |
SARS-CoV-2 (COVID-19) nsp3 | polyclonal | Rabbit | sars coronavirus 2 | Protein A purified | 100 µl | n/a |
GENETEX INC. |
More Info |
SARS-CoV-2 (COVID-19) nsp3 | polyclonal | Rabbit | sars coronavirus 2 | antigen affinity purified | 100 µl | n/a |
GENETEX INC. |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein NTD | monoclonal | Chimeric Human/Mouse | n/a | affinity purified | 100 µg, | n/a |
ABBEXA LTD |
More Info |
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD | polyclonal | Rabbit | n/a | affinity purified | 50 µl, 100 µl, | n/a |
ABBEXA LTD |
More Info |
SARS-CoV-2 (COVID-19) Spike | polyclonal | Sheep | n/a | unconjugated | 0.1 mg | n/a |
BIORBYT LTD. |
More Info |
SARS-CoV-2 Nucleocapsid | 1C7C7 | Recombinant | n/a | unconjugated | 0.1 mg | n/a |
BIORBYT LTD. |
More Info |
SARS-CoV-2 (2019-nCoV) ORF10 | monoclonal | Rabbit | SARS-CoV-2 (2019-nCoV) | unconjugated | n/a | n/a |
CREATIVE BIOLABS, INC. |
More Info |